Our Experts

Name: Fu Jian-Hua
Title: Professor and Director of Guangdong Esophageal Cancer Institute
Email: fujh@sysucc.org.cn

Dr. Jian-Hua Fu is the professor of thoracic cancers and director of Guangdong Esophageal Cancer Institute. Dr. Fu obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 1987 and 2002, respectively, He is one of the most skilled thoracic surgeons in China, especially in the field of minimally invasive esophagectomy. He is the leading specialist in the diagnosis and treatment of Chinese esophageal cancers. He is currently a member of the standing committee of Chinese Anti-Cancer Association (CACA) of Esophageal Cancer, a member of the standing executive committee of Chinese Society of Clinical Oncology (CSCO), a member of Chinese Society for Thoracic and Cardiovascular Surgery (CSTCS), vice-president of Chinese Association of Thoracic Surgeons, president of Guangdong Anti-Cancer Association of Esophageal Cancer, vice-president of Guangdong Medical Association of Oncology. He was rewarded the second class of Guangdong Award for the Scientific and Technological Advancement in 2006, and the third class in 1999, respectively. He has published more than 40 papers in world famous journals, such as Ann Surg, Ann Oncol, J Thorac Oncol, Br J Surg, Br J Cancer, and et al, and over 100 papers in Chinese core journals as the corresponding author or first author.


My primary interest is the comprehensive treatment of esophageal squamous cell carcinomas (ESCCs), and a series of clinical and translational studies were conducted on it. A randomized controlled multi-centre Phase-III trial (Trial registration: NCT01216527) to compare two treatment strategies for ESCC patients at advanced stage, neo-adjuvant chemoradiotherapy (CRT) plus surgery and surgery alone, has completed patient enrollment in 2014. A preliminary analysis of the clinical trial performed in 2013 showed that neo-adjuvant CRT significantly improved R0 resection rate. The cohort of patients receiving neo-adjuvant CRT followed by surgery exhibited better overall and disease-free survival than that of surgery alone. A new Phase-III trial comparing two neo-adjuvant CRT regimens, docetaxol plus cisplatin and vinorelbine plus cisplatin was started in July, 2015, which intends to further optimize ESCC neo-adjuvant CRT strategy. Along with the clinical trial, mRNA and miRNA microarray and high-throughput sequencing studies of pre-treatment tumour biopsies are conducted in ESCC patients who received neo-adjuvant CRT so as to identify molecular markers for patients’ CRT response and survival prediction. Prediction models based on mRNA and miRNA expression were built up, which exhibited good sensitivity and specificity in classifying responders and non-responders after neo-adjuvant CRT.


Bechalor in Medicine, Sun Yat-sen University (1987)

PhD. Sun Yat-sen University (2002)

EMBA, Sun Yat-sen University (2005)



Publication from the past 5 years:                                                                              

1. Huang QY, Luo KJ, Chen C, Wang G, Jin JT, Kong M, Li BF, Liu QW, Li JH, Rong TH, Chen HQ, Zhang LJ, Chen YP, Zhu CC, Zheng B, Wen J, Zheng YZ, Tan ZH, Xie XY, Yang H, Fu JH(corresponding author), Identification and Validation of Lymphovascular Invasion as a Prognostic and Staging Factor in Node-Negative Esophageal Squamous Cell Carcinoma, J Thorac Oncol, 2016 Jan 11. [Epub ahead of print]                                                             

2. Zhang SS, Xie X, Wen J, Luo KJ, Liu QW, Yang H, Hu Y, Fu JH(corresponding author), TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma, Diagn Pathol, 2016, 11(1): 14.                               

3. Wen J, Liu QW, Luo KJ, Ling YH, Xie XY, Yang H, Hu Y, Fu JH(corresponding author), MIIP expression predicts outcomes of surgically resected esophageal squamous cell carcinomas, Tumour Biol. 2016 Jan 29. [Epub ahead of print]    

4. Wen J, Luo KJ, Liu H, Liu SL, Lin GR, Hu Y, Zhang X, Wang G, Chen YP, Chen ZJ, Li Y, Lin T, Xie XY, Liu MZ, Wang HY, Yang H, Fu JH(corresponding author), MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy, Ann Surg, 2015 Oct 1. [Epub ahead of print]                                                                                               

5. Chen JY, Wen J, Zheng YZ, Yang H, Luo KJ, Liu QW, Hu RG, Tan ZH, Huang QY, Fu JH(corresponding author), Prognostic significance of SLC9A9 in patients with resectable esophageal squamous cell carcinoma, Tumour Biol, 2015, 36(9): 6797-6803.                                                                                                         

6. Zheng YZ, Zhao W, Hu Y, Ding-Lin XX, Wen J, Yang H, Liu QW, Luo KJ, Huang QY, Chen JY, Fu JH(corresponding author), Aggressive surgical resection does not improve survival in operable esophageal squamous cell carcinoma with N2-3 status, World J Gastroenterol, 2015, 21(28): 8644-8652.                                                           

7. Chen JY, Yang H, Wen J, Luo KJ, Liu QW, Huang YJ, Zheng YZ, Tan ZH, Huang QY, Fu JH(corresponding author), NHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/beta-catenin pathway and Bcl-2 expression, Oncotarget, 2015, 6(14): 12405-12420.                                                         8. Zheng YZ, Cao X, Wen J, Yang H, Luo KJ, Liu QW, Huang QY, Chen JY, Fu JH(corresponding author), Smoking affects treatment outcome in patients with resected esophageal squamous cell carcinoma who received chemotherapy, PLos One, 2015, 10(4): e0123246-e0123246.    

9. Yang F, Zhang SS, Yang H, Luo KJ, Wen J, Hu Y, Hu RG, Huang QY, Chen JY, Fu JH(corresponding author), Prognostic significance of gamma-glutamyltransferase in patients with resectable esophageal squamous cell carcinoma, Dis Esophagus, 2015, 28(5): 496-504.     

10. Huang QY, Su XD, Bella AE, Luo KJ, Jin JT, Zhang SS, Luo GY, Rong TH, Fu JH(corresponding author), Clinicopathological features and outcome of gastric metastases from primary lung cancer: A case report and systematic review. Oncol Lett, 2015, 9(3): 1373-1379.    

11. Huang QY, Zhong JD, Yang TZ, Li JH, Luo KJ, Zheng YZ, Yang H, Fu JH(corresponding author), Impacts of anastomotic complications on the health-related quality of life after esophagectomy, J Surg Oncol, 2015, 111(4): 365-370.   

12. Ma GW, Zhang X, Ma QL, Rong TH, Long H, Lin P, Fu JH(co-corresponding author), Zhang LJ, A novel multivariate scoring system for determining the prognosis of lymph node-negative esophageal squamous cell carcinoma following surgical therapy: An observational study, Eur J Surg Oncol. 2015, 41(4): 541-547.    

13. Zhu YH, Zhang BZ, Li MQ, Huang PZ, Sun J, Fu JH(co-corresponding author), Guan XY, Prognostic significance of FAM3C in esophageal squamous cell carcinoma. Diagn Pathol. 2015, 10: 192. 

14. Yang F, Zhang S, Yang H, Luo K, Wen J, Hu Y, Hu R, Huang Q, Chen J, Fu JH(corresponding author). Prognostic significance of gamma-glutamyltransferase in patients with resectable esophageal squamous cell carcinoma. Dis Esophagus. 2015, 28(5): 496-504.      

15. Wen J, Yang H, Liu MZ, Luo KJ, Liu H, Hu Y, Zhang X, Lai RC, Lin T, Wang HY, Fu JH (corresponding author). Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy. Ann Oncol. 2014, 25(9): 1769-74.          

16. Bella AE, Zhang YR, Fan W, Luo KJ, Rong TH, Lin P, Yang H, Fu JH(corresponding author). Maximum standardized uptake value on PET/CT in preoperative assessment of lymph node metastasis from thoracic esophageal squamous cell carcinoma. Chin J Cancer, 2014, 33(4): 211-217.   

17. Liu QW, Ma GW, Yang HX, Wen J, Li M, Yang H, Luo KJ, Hu Y, Fu JH(corresponding author), Lack of epidermal growth factor receptor gene mutations in exons 19 and 21 in primary lymphoepithelioma-like carcinoma of the lung, Thorac Cancer, 2014, 5(1): 63-67.    

18. Huang QY, Luo KJ, Yang H, Wen J, Zhang SS, Li JH, Bella AE, Liu QW, Yang F, Zheng YZ, Hu RG, Chen JY, Fu JH(corresponding author), Impact of alcohol consumption on survival in patients with esophageal carcinoma: a large cohort with long-term follow-up, Cancer Sci, 2014, 105(12): 1638-1646.                                                             19. Zhang SS, Yang H, Xie X, Luo KJ, Wen J, Bella AE, Hu Y, Yang F, Fu JH(corresponding author), Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies, Dis Esophagus, 2014, 27(6): 574-584.    

20. Xie X, Zhang SS, Wen J, Yang H, Luo KJ, Yang F, Hu Y, Fu JH(corresponding author), Protein kinase D1 mRNA level may predict cancer-specific survival in heavy smokers with esophageal squamous cell cancers, Dis Esophagus, 2014, 27(2): 188-195.                

21. Zhang SS, Yang H, Luo KJ, Huang QY, Chen JY, Yang F, Cai XL, Xie X, Liu QW, Bella AE, Hu RG, Wen J, Hu Y, Fu JH(corresponding author).The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis. Br J Cancer. 2013;109(11):2894-2903.                                                            22.Yang HX, Feng W, Wei JC, Zeng TS, Li ZD, Zhang LJ, Lin P, Luo RZ, He JH, Fu JH (corresponding author). Support vector machine-based nomogram predicts postoperative distant metastasis for patients with oesophageal squamous cell carcinoma. Br J Cancer. 2013;109(5):1109-1116.  

23. Zhang SS, Wen J, Yang F, Cai XL, Yang H, Luo KJ, Liu QW, Hu RG, Xie X, Huang QY, Chen JY, Fu JH (co-corresponding author), Hu Y. High expression of transient potential receptor C6 correlated with poor prognosis in patients with esophageal squamous cell carcinoma. Med Oncol. 2013;30(3):607.  

24. Xie X, Zhang SS, Wen J, Yang H, Luo KJ, Yang F, Hu Y, Fu JH (corresponding author). Prognostic value of HOXB7 mRNA expression in human oesophageal squamous cell cancer. Biomarkers. 2013 18(4):297-303.    

25. Zhang SS, Huang QY, Yang H, Xie X, Luo KJ, Wen J, Cai XL, Yang F, Hu Y, Fu JH (corresponding author). Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis. Ann Surg Oncol. 2013;20(7):2419-2427.  

26. Wen J, Luo KJ, Hu Y, Yang H, Fu JH(corresponding author). Metastatic lymph node CHIP expression is a potential prognostic marker for resected esophageal squamous cell carcinoma patients. Ann Surg Oncol. 2013;20(5):1668-1675.

27. Wen J, Hu Y, Luo KJ, Yang H, Zhang SS, Fu JH (corresponding author). Positive transforming growth factor-β activated kinase-1 expression has an unfavorable impact on survival in T3N1-3M0 esophageal squamous cell carcinomas. Ann Thorac Surg. 2013;95(1):285-290.      

28. Li XH, Hu Y, Rong TH, Li XD, Su XD, Yang H, Bella AE, Fu JH (corresponding author). Medical thoracoscopy and gastroscopy for the treatment of intrathoracic anastomotic leakage following esophagectomy. Oncol Lett. 2013;5(1):198-200.  

29. Tang J, Deng R, Luo RZ, Shen GP, Cai MY, Du ZM, Jiang S, Yang MT, Fu JH (co-corresponding author), Zhu XF. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 2012;134(2):549-560.                                                                               30. Yang HX, Hou X, Liu QW, Zhang LJ, Liu JG, Lin P, Fu JH (corresponding author). Tumor Location Does Not Impact Long-Term Survival in Patients With Operable Thoracic Esophageal Squamous Cell Carcinoma in China. Ann Thorac Surg. 2012;93(6):1861-1866.    

31. Liu J, Xie X, Zhou C, Peng S, Rao D, Fu J (corresponding author). Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg. 2012;41(3):e7-e11.        

32. Liu J, Hu Y, Xie X, Fu J (corresponding author). Subcarinal node metastasis in thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2012;93(2):423-427.                                                                                 

33. Liu J, Hu Y, Cui C, Li Y, Lin X, Fu J (corresponding author). Removable, Fully Covered, Self-expandable Metal Stents for the Treatment of Refractory Benign Esophagogastric Anastomotic Strictures. Dysphagia. 2012;27(2):260-264.                       

34. Lin X, Wang J, Han F, Fu J (corresponding author), Li A. Analysis of eighty-one cases with breast lesions using automated breast volume scanner and comparison with handheld ultrasound. Eur J Radiol. 2012;81(5):873-878.  34. Luo KJ, Hu Y, Wen J, Fu JH (corresponding author). CyclinD1, p53, E-cadherin, and VEGF discordant expression in paired regional metastatic lymph nodes of esophageal squamous cell carcinoma: A tissue array analysis. J Surg Oncol. 2011;104(3):236-243.                                                                                     

35. Yang HX, Wei JC, Xu Y, Liu JG, Lin P, Rong TH, Fu JH (corresponding author). Modification of nodal categories in the seventh american joint committee on cancer staging system for esophageal squamous cell carcinoma in Chinese patients. Ann Thorac Surg. 2011;92(1):216-224.                                                                                                                              

36. Tang J, Xie XM, Wang X, Xie ZM, He JH, Wu YP, Fan W, Fu JH (co-corresponding author), Yang MT. Radiocolloid in Combination with Methylene Dye Localization, Rather Than Wire Localization, is a Preferred Procedure for Excisional Biopsy of Nonpalpable Breast Lesions. Ann Surg Oncol. 2011;18(1):109-113.  

37. Liu QW, Fu JH (corresponding author), Luo KJ, Yang HX, Wang JY, Hu Y, Yang H, Bella E. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Dis Esophagus. 2011, 24(5):374-380.

Last Updated on: March 2016

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.